Drugs / Oltipraz
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00006457 | Aug 2000 → Apr 2004 | lung cancer | Northwestern University | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT01373554 | May 2011 → Jun 2013 | NAFLD1 | PharmaKing | Completed | Met primary |
| Phase 2 | NCT00956098 | Feb 2006 → Feb 2007 | cirrhosis of liver, fibrotic liver disease | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02068339 | Feb 2014 → Feb 2016 | NAFLD1 | PharmaKing | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04142749 Comparator | Nov 2019 → Sep 2022 | NAFLD1 | PharmaKing | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oltipraz | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04142749 ↗ |
| Known as | 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione | “Oltipraz \[5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione\] has been extensively studied as a cancer chemopreventive agent.” NCT00956098 ↗ |
| Known as | NSC-347901 | ChEMBL registry synonym — accepted as the source's own label CHEMBL178459 ↗ |
| Action | Inhibit | “Oltipraz is a synthetic dithiolethione with an antisteatotic effect by inhibiting the activity of liver X receptor alpha (LXR-α).” PMID 28225186 ↗ Feb 2017 |
| Modality | Small molecule | “Oltipraz is a synthetic dithiolethione” PMID 28225186 ↗ Feb 2017 |
| Route | Oral | “Patients receive low-dose oral oltipraz weekly.” NCT00006457 ↗ |
| Target | S6K1 | “modulation of S6K1 by oltipraz inhibited the development of insulin resistance and hyperglycemia through the AMPK-S6K1 pathway” NCT04142749 ↗ |
| Target | SREBP-1c | “Oltipraz inhibits fatty acid synthesis through AMPK-S6K1 pathway and LXRg-SREBP-1c pathway in liver.” NCT04142749 ↗ |